Foster® pMDI (CHF 1535) Versus Symbicort® Turbohaler in COPD Patient
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to demonstrate the non-inferiority of CHF1535 pMDI versus
Symbicort® Turbohaler® in terms of lung function parameters and patients reported outcomes
and to assess its safety and tolerability.
Phase:
Phase 3
Details
Lead Sponsor:
Chiesi Farmaceutici S.p.A.
Treatments:
Beclomethasone Budesonide Budesonide, Formoterol Fumarate Drug Combination Formoterol Fumarate